PMID- 29171913
OWN - NLM
STAT- MEDLINE
DCOM- 20180814
LR  - 20180814
IS  - 1600-0609 (Electronic)
IS  - 0902-4441 (Linking)
VI  - 100
IP  - 3
DP  - 2018 Mar
TI  - MONITOR-GCSF DLBCL subanalysis: Treatment patterns/outcomes with biosimilar 
      filgrastim for chemotherapy-induced/febrile neutropenia prophylaxis.
PG  - 241-246
LID - 10.1111/ejh.13002 [doi]
AB  - OBJECTIVE: Prospective data on the use of granulocyte-colony-stimulating factor 
      (G-CSF) in non-Hodgkin's lymphoma and its aggressive subtypes, including diffuse 
      large B-cell lymphoma (DLBCL), are limited. MONITOR-GCSF is a pan-European, 
      multicenter, prospective, observational study aiming to describe treatment 
      patterns and clinical outcomes in patients receiving biosimilar filgrastim in the 
      prophylaxis of chemotherapy-induced neutropenia (CIN) and febrile neutropenia 
      (FN). METHODS: This analysis describes patient characteristics, treatment 
      patterns, and outcomes for 245 patients with stage 3 or 4 DLBCL receiving </=6 
      chemotherapy cycles as part of MONITOR-GCSF study, including patients aged 
      >/=65 years and >/=70 years. Outcomes of interest included the incidence of CIN and 
      FN, antibiotic prophylaxis, biosimilar filgrastim prophylaxis, and adverse events 
      (AEs). RESULTS: MONITOR-GCSF included 245 patients with DLBCL. Of these patients, 
      87 (35.5%) experienced one or more CIN (any grade) episode and 24 (9.8%) 
      experienced FN (any grade). The most frequent AE reported was bone pain (n = 7, 
      2.9%), followed by arthralgia (n = 2, 0.8%) and back pain (n = 2, 0.8%). 
      CONCLUSION: In real-life practice, biosimilar filgrastim demonstrated clinical 
      effectiveness and safety in patients with DLBCL. The large percentage of patients 
      aged >/=65 years adds to the evidence on how to best treat older patients with 
      DLBCL receiving myelosuppressive chemotherapy.
CI  - (c) 2017 The Authors. European Journal of Haematology Published by John Wiley &Sons 
      Ltd.
FAU - Gascon, Pere
AU  - Gascon P
AD  - Department of Hematology-Oncology, University of Barcelona, Barcelona, Spain.
FAU - Krendyukov, Andriy
AU  - Krendyukov A
AD  - Sandoz Biopharmaceuticals/Hexal AG, Holzkirchen, Germany.
FAU - Hobel, Nadja
AU  - Hobel N
AD  - Sandoz Biopharmaceuticals/Hexal AG, Holzkirchen, Germany.
FAU - Aapro, Matti
AU  - Aapro M
AD  - Institut Multidisciplinaire d'Oncologie, Clinique de Genolier, Genolier, 
      Switzerland.
LA  - eng
PT  - Journal Article
PT  - Multicenter Study
PT  - Observational Study
DEP - 20171229
PL  - England
TA  - Eur J Haematol
JT  - European journal of haematology
JID - 8703985
RN  - 0 (Anti-Bacterial Agents)
RN  - 0 (Biosimilar Pharmaceuticals)
RN  - 0 (Hematologic Agents)
RN  - 0 (Myeloablative Agonists)
RN  - PVI5M0M1GW (Filgrastim)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Anti-Bacterial Agents/administration & dosage
MH  - Antineoplastic Combined Chemotherapy Protocols/administration & dosage/adverse 
      effects
MH  - Arthralgia/chemically induced/physiopathology/prevention & control
MH  - Back Pain/chemically induced/physiopathology/prevention & control
MH  - Bacterial Infections/prevention & control
MH  - Biosimilar Pharmaceuticals/*therapeutic use
MH  - Bone and Bones/drug effects/physiopathology
MH  - Febrile Neutropenia/chemically induced/physiopathology/*prevention & control
MH  - Female
MH  - Filgrastim/*therapeutic use
MH  - Hematologic Agents/*therapeutic use
MH  - Humans
MH  - Lymphoma, Large B-Cell, Diffuse/*drug therapy/pathology
MH  - Male
MH  - Middle Aged
MH  - Myeloablative Agonists/administration & dosage/adverse effects
MH  - Neoplasm Staging
MH  - Patient Safety
MH  - Prospective Studies
MH  - Treatment Outcome
OTO - NOTNLM
OT  - non-Hodgkin's lymphoma
OT  - socio-economics and ethics
OT  - supportive care
EDAT- 2017/11/25 06:00
MHDA- 2018/08/15 06:00
CRDT- 2017/11/25 06:00
PHST- 2017/11/17 00:00 [accepted]
PHST- 2017/11/25 06:00 [pubmed]
PHST- 2018/08/15 06:00 [medline]
PHST- 2017/11/25 06:00 [entrez]
AID - 10.1111/ejh.13002 [doi]
PST - ppublish
SO  - Eur J Haematol. 2018 Mar;100(3):241-246. doi: 10.1111/ejh.13002. Epub 2017 Dec 
      29.